Oppenheimer began coverage on shares of ANCHIANO THERAP/S (NASDAQ:ANCN) in a report issued on Monday morning, The Fly reports. The brokerage issued an outperform rating and a $16.00 price objective on the stock.
Shares of ANCHIANO THERAP/S stock opened at $7.56 on Monday. ANCHIANO THERAP/S has a 52 week low of $7.33 and a 52 week high of $11.50.
About ANCHIANO THERAP/S
Anchiano Therapeutics Ltd, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to treat cancer-related diseases. It is primarily developing Inodiftagene vixteplasmid for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd.
Read More: Trading Ex-Dividend Strategy
Receive News & Ratings for ANCHIANO THERAP/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANCHIANO THERAP/S and related companies with MarketBeat.com's FREE daily email newsletter.